GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Cyclically Adjusted FCF per Share

Merus NV (Merus NV) Cyclically Adjusted FCF per Share : $-2.76 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Merus NV Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Merus NV's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.628. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-2.76 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-01), Merus NV's current stock price is $45.30. Merus NV's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-2.76. Merus NV's Cyclically Adjusted Price-to-FCF of today is .


Merus NV Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Merus NV's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Cyclically Adjusted FCF per Share Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -2.76

Merus NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -2.76

Competitive Comparison of Merus NV's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Merus NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merus NV's Cyclically Adjusted Price-to-FCF falls into.



Merus NV Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merus NV's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.628/126.4000*126.4000
=-0.628

Current CPI (Dec. 2023) = 126.4000.

Merus NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 98.360 0.000
201406 0.000 99.240 0.000
201409 0.000 99.960 0.000
201412 0.000 99.050 0.000
201503 -0.313 99.750 -0.397
201506 -0.283 100.230 -0.357
201509 -0.545 100.500 -0.685
201512 -0.500 99.730 -0.634
201603 -0.537 100.310 -0.677
201606 -0.515 100.260 -0.649
201609 -0.331 100.570 -0.416
201612 -0.521 100.710 -0.654
201703 -0.384 101.440 -0.478
201706 -0.582 101.370 -0.726
201709 -0.788 102.030 -0.976
201712 -0.620 101.970 -0.769
201803 -0.775 102.470 -0.956
201806 -0.091 103.100 -0.112
201809 -0.835 103.950 -1.015
201812 -0.576 103.970 -0.700
201903 -0.604 105.370 -0.725
201906 -0.689 105.840 -0.823
201909 -0.657 106.700 -0.778
201912 -0.751 106.800 -0.889
202003 -0.878 106.850 -1.039
202006 -0.653 107.510 -0.768
202009 -0.414 107.880 -0.485
202012 -0.826 107.850 -0.968
202103 0.530 108.870 0.615
202106 -0.636 109.670 -0.733
202109 -0.606 110.790 -0.691
202112 -0.771 114.010 -0.855
202203 -1.075 119.460 -1.137
202206 -0.793 119.050 -0.842
202209 -0.946 126.890 -0.942
202212 -0.704 124.940 -0.712
202303 -0.871 124.720 -0.883
202306 -0.868 125.830 -0.872
202309 -0.512 127.160 -0.509
202312 -0.628 126.400 -0.628

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Merus NV  (NAS:MRUS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Merus NV Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Merus NV's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (Merus NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Cyclically Adjusted FCF per Share
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM